60,689 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by May Hill Capital LLC

May Hill Capital LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 60,689 shares of the medical equipment provider's stock, valued at approximately $5,421,000. Boston Scientific comprises approximately 2.1% of May Hill Capital LLC's portfolio, making the stock its 9th biggest holding.

Several other institutional investors have also added to or reduced their stakes in BSX. Norges Bank bought a new position in Boston Scientific during the fourth quarter worth $1,762,522,000. Wellington Management Group LLP raised its position in shares of Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after acquiring an additional 3,344,571 shares in the last quarter. Axiom Investors LLC DE boosted its position in shares of Boston Scientific by 208.2% during the 4th quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock valued at $335,167,000 after purchasing an additional 2,535,007 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Boston Scientific during the fourth quarter worth approximately $190,780,000. Finally, Vanguard Group Inc. increased its holdings in Boston Scientific by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock worth $11,869,805,000 after purchasing an additional 1,600,062 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 133,183 shares of company stock valued at $13,948,476 in the last 90 days. Insiders own 0.50% of the company's stock.

Remove Ads

Boston Scientific Stock Performance

BSX traded down $8.73 during trading on Friday, hitting $89.78. 22,572,180 shares of the company traded hands, compared to its average volume of 6,188,157. Boston Scientific Co. has a one year low of $66.80 and a one year high of $107.17. The stock's fifty day moving average is $101.90 and its 200 day moving average is $93.63. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market cap of $132.78 billion, a P/E ratio of 71.82, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, equities analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on BSX shares. Morgan Stanley boosted their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research report on Monday, March 3rd. Royal Bank of Canada boosted their target price on Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. TD Cowen raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, December 12th. Finally, Wells Fargo & Company upped their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.